Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

Open access
Wang, Liang, Wang, Hua, Chen, Hao, Wang, Wei-da, Chen, Xiao-qin, Geng, Qi-rong, Xia, Zhong-jun, Lu, Yue·2015·Oncotarget

Abstract

// Liang Wang 1, 2, * , Hua Wang 1, 2, * , Hao Chen 1, 3, * , Wei-da Wang 1, 2 , Xiao-qin Chen 1, 2 , Qi-rong Geng 1, 2 , Zhong-jun Xia 1, 2 , Yue Lu 1, 2 1 State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China 2 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China 3 Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Yue Lu, e-mail: luyuesysucc@126.com Keywords: multiple myeloma, programmed death-ligand 1, immune checkpoint, prognosis, biomarker Received: May 31, 2015 Accepted: September 13, 2015 Published: October 16, 2015 ABSTRACT Immune checkpoint signaling plays an important role in immunosuppression in multiple myeloma (MM). Blood levels of soluble programmed death-ligand 1 (sPD-L1), a checkpoint-relevant protein, might predict treatment response and survival outcomes in MM patients. We used an enzyme-linked immunosorbent assay to measure serum sPD-L1 levels in 81 newly diagnosed MM patients. We found that myeloma patients had higher sPD-L1 concentrations than healthy controls. The best sPD-L1 cutoff value for predicting disease progression risk was 2.783 ng/mL. The overall response rate to treatment was higher in low sPD-L1 patients than in high sPD-L1 patients. The 3-year progression free survival (PFS) and overall survival (OS) rates for all patients were 16% and 64%, respectively. Multivariate survival analysis including Eastern Cooperative Oncology Group performance status score, treatment response, and sPD-L1 level showed that a less than partial treatment response (PR) and higher sPD-L1 levels (>2.783 ng/ml) were independent prognostic factors for shorter PFS; neither factor was predictive of OS. The serum sPD-L1 level is a valuable biomarker for predicting treatment response and an independent prognostic factor for PFS. PD-1/ PD-L1 blockade may be a promising novel immune-based therapeutic strategy in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5682

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 179

Metadata

Authors
Wang, L., Wang, H., Chen, H., Wang, W.-D., Chen, X.-Q., Geng, Q.-R., Xia, Z.-J., & Lu, Y.
Venue
Oncotarget
Published
2015-10-16
Volume
6
Issue
38
Pages
41228-41236
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2267145540
Cited by
179
References
4
FWCI
12.89
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. https://app.cochat.ai/papers/10.18632/oncotarget.5682
The paper
Wang, L., Wang, H., Chen, H., Wang, W.-D., Chen, X.-Q., Geng, Q.-R., Xia, Z.-J., & Lu, Y. (2015). Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. https://doi.org/10.18632/oncotarget.5682

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.